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Abstract: The relationship between mitochondrial DNA (mtDNA) and breast cancer has been
frequently examined, particularly in European populations. However, studies reporting associations
between mtDNA haplogroups and breast cancer risk have had a few shortcomings including small
sample sizes, failure to account for population stratification and performing inadequate statistical
tests. In this study we investigated the association of mtDNA haplogroups of European origin
with several breast cancer risk factors in mothers and children of the Avon Longitudinal Study of
Parents and Children (ALSPAC), a birth cohort that enrolled over 14,000 pregnant women in the
Southwest region of the UK. Risk factor data were obtained from questionnaires, clinic visits and
blood measurements. Information on over 40 independent breast cancer risk factor-related variables
was available for up to 7781 mothers and children with mtDNA haplogroup data in ALSPAC.
Linear and logistic regression models adjusted for age, sex and population stratification principal
components were evaluated. After correction for multiple testing we found no evidence of association
of European mtDNA haplogroups with any of the breast cancer risk factors analysed. Mitochondrial
DNA haplogroups are unlikely to underlie susceptibility to breast cancer that occurs via the risk
factors examined in this study of a population of European ancestry.
Keywords: mitochondrial DNA; haplogroups; breast cancer; risk factors; ALSPAC; Europeans
1. Introduction
The relationship between mitochondrial DNA (mtDNA) and breast cancer has been frequently
explored. Carcinogenesis has been associated with oxidative stress, with mitochondria acting as a
major source of production of reactive oxygen species (ROS) [1]. Additionally, the lack of protective
histones and a limited capacity for DNA repair [2,3] has meant that the mitochondrial genome is
particularly susceptible to damage by ROS, which in turn could affect the mitochondrial role in energy
metabolism, apoptosis and aging [4]. Most publications have focused on somatic mutations in mtDNA.
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However, germline variants that subtly affect mitochondrial functioning may also lead to a build-up
of ROS, resulting in an elevated cancer risk [4], and their study has thus become more frequent [5].
Since mtDNA is maternally inherited, it has been suggested that it could underlie the observation
that having a mother diagnosed with breast cancer increases a woman’s risk of the disease.
During evolution mtDNA mutations have segregated and clustered in groups of related
haplotypes or haplogroups (also referred to as clades) that differ prominently in frequencies across
continents [6,7]. The geographic patterning of mtDNA lineages was attributed to founder effects
although natural selection has been recently postulated as a more probable cause. Adaptation to
climate and nutrition may have been the environmental selective factors to drive clade differences
by region given that haplogroups exhibit diverse metabolic capacities [6,8]. Thus, lineages that are
advantageous in a particular environment could become maladaptive when the environment changes
contributing to the development of disease.
Nine major mtDNA haplogroups have been identified in Europeans (namely H, I, J, K, T, U, V,
W, X). Haplogroup H is the most frequent, though the frequencies of individual clades vary within
Europe [9].
The association of mtDNA variants and haplogroups with cancer and other diseases has been
extensively explored in the European population. For instance, there are reports on breast cancer [10,11],
prostate cancer [12], meningococcal disease [13], neurological diseases [14], type 2 diabetes mellitus [15],
infertility [16], obesity [17], acquired immunodeficiency syndrome (AIDS) progression [18], stroke [19],
and osteoarthritis [20]. Results have been inconsistent across studies of the same disease. This has
been attributed to a number of problems relating to study design and data analysis, such as population
stratification, genotyping error, small sample sizes or inadequate statistical approaches [21–24].
The case of breast cancer studies is particularly noteworthy [23].
In order to elucidate the putative role of mtDNA in breast cancer we investigated the distribution
of European mtDNA haplogroups across a range of well-known and possible risk factors for breast
cancer in mothers and children of the Avon Longitudinal Study of Parents and Children (ALSPAC).
If mtDNA variation plays a role in breast cancer susceptibility it may do so via risk factors that lie in
the causal pathway to disease. Thus, we might be able to detect an association of mtDNA haplogroups
with these exposures with less bias in a large and substantially homogeneous cohort like ALSPAC.
2. Materials and Methods
2.1. Avon Longitudinal Study of Parents and Children (ALSPAC)
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective, population-based
birth cohort study that recruited 14,541 pregnant women residing in Avon County, United Kingdom,
with an expected delivery date between 1 April 1991 and 31 December 1992. From these initial
pregnancies, there were a total of 14,676 fetuses, resulting in 14,062 live births and 13,988 children
who were alive at one year of age. When the oldest children were approximately seven years of
age, an attempt was made to bolster the initial sample with eligible cases who had failed to join
the study originally. The total sample size for analyses using any data collected after the age of
seven is therefore 15,247 pregnancies, resulting in 15,458 fetuses, of which 14,775 were live births and
14,701 were alive at one year of age. Data were gathered through self-completed questionnaires or
assessment at research clinics at regular intervals. The study is described in detail elsewhere [25,26]
(http://www.bristol.ac.uk/alspac/). Hormone level measurements (i.e., circulating sex hormones,
insulin growth factors and insulin growth factor binding proteins) were reported earlier [27–31].
Please note that the study website contains details of all the data that are available through a fully
searchable data dictionary: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the
Local Research Ethics Committees (http://www.bristol.ac.uk/alspac/researchers/research-ethics/).
Written informed consent was obtained from all participants in the study.
Genes 2018, 9, 395 3 of 31
2.2. Breast Cancer Risk Factors
The selection of breast cancer risk factors was based on worldwide research data published by the
World Cancer Research Fund [32] and Cancer Research UK [33].
Lifestyle factors showing robust evidence for increasing the risk of breast cancer have
been identified in premenopausal women, postmenopausal women, or both. Risk factors for
postmenopausal breast cancer are: overweight or obesity and a greater weight gain in adulthood.
Having a greater birth weight is a risk factor for premenopausal breast cancer. Alcohol intake and
a greater linear growth (marked by adult attained height) have been associated with both pre- and
postmenopausal breast cancer. Conversely, factors that reduce the risk of breast cancer include
increased physical activity, and breastfeeding, whereas being overweight or obese acts as a protective
factor in premenopausal women.
Other established risk factors are older age, White ethnicity, family history of breast cancer, a prior
diagnosis of cancer, early menarche, late natural menopause, nulliparity, first pregnancy after the age
of 30, hormone replacement therapy, use of oral contraceptives, high bone mineral density, diabetes
mellitus and exposure to radiation such as X-rays.
Possible breast cancer risk factors include smoking and night shift work. In contrast, a healthy
diet and regularly taking aspirin or other non-steroidal anti-inflammatory drugs are considered
protective factors.
We also tested women having had reproductive surgery (hysterectomy and/or oophorectomy),
and using non-oral hormonal contraceptives, which may affect breast cancer risk by altering
hormone concentrations, and serum levels of sex hormone binding globulin (SHBG), testosterone,
androstenedione, dehydroepiandrosterone-sulfate (DHEAS), insulin like growth factor I (IGF-I),
insulin-like growth factor II (IGF-II) and insulin-like growth factor binding protein 3 (IGFBP-3).
More detailed information on the association of the risk factors considered with breast cancer can
be found in the literature [34–38].
Data on most risk and protective factors were available in ALSPAC from mothers, children or both.
2.3. Variables Analyzed
Details on the continuous and categorical variables examined in mothers and children are given
in Tables S1 and S2 showing the complete set of ALSPAC participants of European ancestry. Data were
obtained from questionnaires answered by the subject or by the subject’s mother during childhood,
as well as from clinic visits at different time points. We limited the analysis to variables measured
approximately every two years in the children.
In some cases, usually when numbers were low, we created new variables that reflected whether
the individual had ever experienced the activity or shown the trait of interest by combining the
different instances where it was assessed. We did this for smoking, having diabetes, having had
cancer, having undergone a hysterectomy and/or an oophorectomy, doing night shift work, taking
oral contraceptives, using non-oral hormonal contraceptives, receiving hormone replacement therapy,
taking aspirin, being a biological parent, undertaking physical activity and getting X-rays. The variable
age of menarche in the children was determined by integrating all the information provided by the
mother and the child [39].
2.4. Mitochondrial DNA Genotyping
Genotyping methods for mitochondrial and nuclear DNA polymorphisms in ALSPAC have
been previously described [40]. Haplogroup assignment was performed using HaploGrep [41].
Mitochondrial DNA haplogroups of mothers were inferred from those of their children in view
of the maternal inheritance of mtDNA.
Samples with a quality score of more than 80% were included in the analysis (238 samples were
excluded, Table S3). Additionally, we ran the analysis using a quality score cut-off point of >90%.
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We grouped the clades as follows: European = H (H + V + subclade R0), J, K, T, U, other European
(I + W + X + subclades N1, R1, R3); South Asian = M + subclade R5; East/Southeast Asian = A + C + D;
and African = L. The ‘other European’ group consisted of haplogroups that were present in less than
3% of the sample.
We restricted our analysis to all individuals who were of European genomic ancestry (as detected
by a multidimensional scaling analysis seeded with haplotype map (HapMap)2 individuals) or
self-identified as White (if data on genomic ancestry was missing) and carried a European mtDNA
haplogroup. There was information on 7781 mtDNA haplogroups in our working dataset.
2.5. Statistical Analysis
We used linear regression to investigate the association of continuous variables with mtDNA
haplogroups and chi-squared tests to examine differences in categorical variables. Adjustment for
confounders was carried out using linear and logistic regression models with continuous and
categorical variables, respectively. When categorical variables exhibited more than two ordered
categories ordinal logistic regression was run, also adjusted for confounders. Confounders introduced
in the models were age, sex, gestational age and the top 10 principal components accounting for
population stratification, where appropriate.
We checked that the residuals of the linear regression of each continuous variable on mtDNA
haplogroups were normally distributed. Only residuals for DHEAS levels in children showed a
markedly non-normal distribution, and therefore the variable was natural log-transformed [42].
Similarly to Howe et al. [40], we used pairwise correlation to determine the number of independent
variables to account for when applying the Bonferroni correction for multiple testing [43]. Polychoric
correlation was used with binary and ordinal variables. Variables showing a correlation coefficient
of 0.8 and above were considered non-independent (data not shown). There were 43 independent
variables (out of 59) in the mothers and 48 independent variables (out of 86) in the children, therefore
the multiple testing adjusted p-value cut-off was 0.001 in both cases.
We tested whether there was residual population stratification due to mtDNA clustering within
our working dataset of European/White individuals by plotting the top two principal components
by mitochondrial lineage as reported by Erzurumluoglu et al. for Y chromosome haplogroups in
ALSPAC [44].
All analyses were performed with the statistical package Stata 14 (StataCorp, College Station,
TX, USA).
Statistical power was calculated with mitPower using binary variables, as this approach
has not been developed for continuous or ordinal variables yet (http://bioinformatics.cesga.es/
mitpower/) [45].
3. Results
Mitochondrial DNA haplogroups found in mothers and children of ALSPAC that were used in
this study are shown in Table 1. For a more detailed haplogroup report see Table S3. The most frequent
haplogroup was HV, representing almost 50% of the sample (49.3%), in agreement with the probable
haplogroup composition of the UK estimated in a recent mtDNA study [46].
It is interesting to note, although not completely unexpected [47], that despite selecting individuals
of European genomic ancestry and White ethnicity around 1% of them carried non-European mtDNA
haplogroups (i.e., A, C, D, L, M, N) (Table S3), and were therefore excluded from the analysis. This can
also be observed in individuals with an mtDNA quality score over 90% (Table S3). We uncovered no
evidence of residual population stratification in the group of participants who carried a European
mtDNA haplogroup (Figures S1 and S2).
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Table 1. European mitochondrial DNA haplogroups in mothers and children of the Avon Longitudinal
Study of Parents and Children (ALSPAC) used in the analysis of breast cancer risk factors (quality score
> 80%).
mtDNA Haplogroups N %
HV 3835 49.3
U 1060 13.6
J 873 11.2
T 817 10.5
K 694 8.9
Other European 502 6.5
Total 7781 100.0
mtDNA: Mitochondrial DNA.
No differences were identified in the distribution of mtDNA haplogroups by sex of the child
(p = 0.15).
In the unadjusted analyses sample sizes ranged from 143 to 7629 in the mothers, and from 142 to
7373 in the children, whereas sample sizes for the adjusted analyses were between 100 and 4863, and
between 137 and 6838, respectively.
Given the sample sizes available for the binary variables, the haplogroup frequencies and the
number of haplogroups included in the analysis, we had 80% power to detect odds ratios (OR) of
~1.2 (ever smoked) to 1.7 (being a biological parent) at an α level of 0.05 if considering HV as the
risk haplogroup. Under the same conditions, at the significance level corrected for multiple testing
(p ≤ 0.001), those ORs become ~1.3 to 2.1. This calculation excludes the variable ‘having diabetes’ in
children as there were only 26 subjects with the disease and mtDNA data in ALSPAC.
3.1. Association between Mitochondrial DNA Haplogroups and Breast Cancer Risk Factors in
ALSPAC Mothers
In the unadjusted analysis 10 nominal associations of mtDNA haplogroups with breast cancer risk
factors were found (p ≤ 0.05). Most of these associations involved body composition variables such as
body mass index (BMI), weight, height and bone mineral density (Table S4). Seven associations were
apparent after correction for age (or gestational age in the case of IGF and sex hormone measurements in
pregnancy) and the top 10 principal components (Table 2). However, no strong evidence of association
was present after applying a Bonferroni correction for multiple testing.
3.2. Association between Mitochondrial DNA Haplogroups and Breast Cancer Risk Factors in
ALSPAC Children
Likewise, among the children no associations between mtDNA haplogroups and breast cancer
risk factors were uncovered after multiple testing correction. All three associations showing a p ≤ 0.05
in unadjusted models were related to BMI and height (Table S5) and two of these were also detected
after controlling for age, sex and the top 10 principal components (Table 3).
Similar results overall were obtained when using the more stringent quality score threshold of
>90% (Table S6).
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Table 2. Major European mitochondrial DNA (mtDNA) haplogroups and breast cancer risk factors in ALSPAC mothers. Regression models adjusted for age and the
top 10 genomic principal components. (A) Continuous variables; (B) categorical variables. Reference is haplogroup HV.
A-Variable Clade Beta 95% CI p-Value N Model p-Value
SHBG(nmol/L) in pregnancy 1 U −40.28 (−136.56,56.01) 0.408 101 0.338
J −79.04 (−180.04,21.95) 0.123 101
T 40.96 (−48.11,130.02) 0.363 101
K 21.84 (−79.84,123.52) 0.670 101
Other European −64.39 (−205.90,77.11) 0.368 101
Testosterone (nmol/L) in pregnancy 1 U −0.32 (−1.16,0.52) 0.444 100 0.228
J −0.10 (−0.98,0.77) 0.813 100
T 0.15 (−0.63,0.93) 0.705 100
K 0.98 (0.09,1.86) 0.031 100
Other European −0.02 (−1.25,1.21) 0.972 100
IGF-I (ng/mL) in pregnancy 1 U 4.21 (−19.23,27.66) 0.724 231 0.709
J 2.53 (−21.74,26.81) 0.837 231
T −2.67 (−25.40,20.05) 0.817 231
K −14.90 (−42.78,12.99) 0.294 231
Other European 16.08 (−12.44,44.61) 0.268 231
IGF-II (ng/mL) in pregnancy 1 U 34.45 (−51.06,119.97) 0.428 224 0.232
J −2.32 (−89.70,85.06) 0.958 224
T −32.26 (−116.26,51.74) 0.450 224
K 105.67 (2.40,208.93) 0.045 224
Other European 61.39 (−41.29,164.06) 0.240 224
IGFBP-3 (ng/mL) in pregnancy 1 U −371.92 (−926.11,182.27) 0.187 231 0.023
J 67.20 (−506.61,641.01) 0.818 231
T −474.38 (−1011.50,62.74) 0.083 231
K 772.03 (112.93,1431.12) 0.022 231
Other European 381.81 (−292.51,1056.13) 0.266 231
Mother’s natural mother’s age at birth (years) U 0.08 (−0.44,0.60) 0.769 4164 0.985
J −0.04 (−0.61,0.52) 0.878 4164
T 0.14 (−0.42,0.70) 0.626 4164
K 0.18 (−0.43,0.78) 0.562 4164
Other European 0.11 (−0.60,0.83) 0.761 4164
Age of mother at birth (years) U 0.06 (−0.35,0.46) 0.791 4441 0.591
J 0.32 (−0.13,0.76) 0.162 4441
T −0.16 (−0.60,0.29) 0.493 4441
K 0.15 (−0.33,0.62) 0.549 4441
Other European −0.17 (−0.73,0.39) 0.554 4441
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Table 2. Cont.
A-Variable Clade Beta 95% CI p-Value N Model p-Value
Age at menarche (years) U −0.02 (−0.16,0.12) 0.807 4073 0.043
J −0.17 (−0.32,−0.01) 0.032 4073
T −0.19 (−0.35,−0.04) 0.013 4073
K 0.05 (−0.11,0.22) 0.535 4073
Other European −0.11 (−0.30,0.09) 0.271 4073
Age at menopause (years) (child ~20 years old) U 0.95 (0.07,1.82) 0.034 877 0.329
J −0.09 (−1.02,0.84) 0.845 877
T −0.16 (−1.20,0.89) 0.766 877
K −0.15 (−1.12,0.83) 0.769 877
Other European −0.16 (−1.37,1.06) 0.802 877
Birth weight of mother (g) U −34.42 (−101.56,32.72) 0.315 2906 0.760
J −33.85 (−107.72,40.03) 0.369 2906
T −6.93 (−78.36,64.50) 0.849 2906
K −26.06 (−103.86,51.74) 0.511 2906
Other European 31.84 (−61.43,125.10) 0.503 2906
BMI (~12 weeks gestation) U 0.20 (−0.15,0.55) 0.260 4229 0.028
J 0.60 (0.22,0.98) 0.002 4229
T 0.22 (−0.16,0.60) 0.259 4229
K 0.42 (0.02,0.83) 0.040 4229
Other European 0.02 (−0.47,0.50) 0.940 4229
BMI (May–September 2010) U 0.41 (−0.36,1.19) 0.299 1503 0.713
J 0.45 (−0.38,1.27) 0.286 1503
T −0.02 (−0.90,0.85) 0.956 1503
K −0.28 (−1.16,0.60) 0.535 1503
Other European 0.18 (−0.83,1.19) 0.727 1503
BMI (FOM1: 2009–2011) U 0.27 (−0.35,0.90) 0.389 2565 0.175
J 0.58 (−0.08,1.25) 0.086 2565
T −0.44 (−1.13,0.25) 0.213 2565
K 0.32 (−0.40,1.05) 0.381 2565
Other European 0.54 (−0.32,1.39) 0.218 2565
BMI (FOM2: 2011–2013) U 0.68 (−0.09,1.45) 0.084 1649 0.438
J 0.54 (−0.28,1.36) 0.195 1649
T −0.13 (−1.02,0.75) 0.769 1649
K 0.06 (−0.84,0.95) 0.900 1649
Other European 0.40 (−0.61,1.42) 0.434 1649
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Table 2. Cont.
A-Variable Clade Beta 95% CI p-Value N Model p-Value
Pre-pregnancy weight (kg) U 1.07 (0.07,2.07) 0.036 4272 0.035
J 1.54 (0.46,2.62) 0.005 4272
T 0.95 (−0.14,2.04) 0.088 4272
K 1.01 (−0.15,2.17) 0.087 4272
Other European 0.50 (−0.88,1.88) 0.478 4272
Weight (kg) (May–September 2010) U 1.70 (−0.43,3.84) 0.118 1512 0.417
J 0.77 (−1.51,3.05) 0.509 1512
T −0.20 (−2.60,2.19) 0.869 1512
K −1.16 (−3.59,1.27) 0.349 1512
Other European 1.18 (−1.62,3.98) 0.410 1512
Weight (kg) (FOM1: 2009–2011) U 1.10 (−0.63,2.83) 0.213 2565 0.288
J 1.21 (−0.63,3.06) 0.198 2565
T −0.50 (−2.41,1.41) 0.609 2565
K 0.61 (−1.39,2.61) 0.550 2565
Other European 2.18 (−0.18,4.53) 0.071 2565
Weight (kg) (FOM2: 2011–2013) U 2.53 (0.39,4.66) 0.020 1649 0.294
J 1.20 (−1.05,3.45) 0.295 1649
T 0.79 (−1.65,3.22) 0.528 1649
K 0.52 (−1.95,3.00) 0.678 1649
Other European 1.52 (−1.28,4.32) 0.287 1649
Height (cm) (~12 weeks gestation) U 0.66 (0.05,1.27) 0.034 4434 0.134
J −0.26 (−0.91,0.40) 0.438 4434
T 0.36 (−0.30,1.02) 0.288 4434
K −0.23 (−0.93,0.48) 0.529 4434
Other European 0.43 (−0.41,1.27) 0.315 4434
Height (cm) (May–September 2010) U 0.80 (−0.15,1.74) 0.098 1745 0.241
J −0.60 (−1.60,0.41) 0.244 1745
T −0.09 (−1.14,0.97) 0.873 1745
K −0.48 (−1.57,0.61) 0.389 1745
Other European 0.46 (−0.79,1.71) 0.467 1745
Height (cm) (FOM1: 2009–2011) U 0.48 (−0.25,1.21) 0.198 2565 0.060
J −0.40 (−1.18,0.38) 0.320 2565
T 0.91 (0.10,1.72) 0.028 2565
K −0.29 (−1.14,0.56) 0.510 2565
Other European 0.68 (−0.32,1.68) 0.181 2565
Sitting height (cm) (FOM1: 2009–2011) U 0.36 (−0.03,0.75) 0.073 2545 0.057
J 0.10 (−0.32,0.52) 0.637 2545
T 0.63 (0.20,1.06) 0.004 2545
K 0.05 (−0.40,0.50) 0.837 2545
Other European 0.35 (−0.18,0.88) 0.193 2545
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Table 2. Cont.
A-Variable Clade Beta 95% CI p-Value N Model p-Value
Leg length (cm) (FOM1: 2009–2011) U 0.11 (−0.38,0.60) 0.670 2545 0.170
J −0.43 (−0.95,0.10) 0.111 2545
T 0.31 (−0.24,0.85) 0.270 2545
K −0.34 (−0.90,0.23) 0.245 2545
Other European 0.36 (−0.30,1.03) 0.286 2545
Height (cm) (FOM2: 2011–2013) U 0.91 (0.00,1.81) 0.049 1649 0.041
J −0.38 (−1.33,0.58) 0.439 1649
T 1.36 (0.32,2.39) 0.010 1649
K 0.42 (−0.63,1.47) 0.434 1649
Other European 0.46 (−0.73,1.64) 0.449 1649
Sitting height (cm) (FOM2: 2011–2013) U 0.54 (0.09,1.00) 0.020 1648 0.016
J 0.19 (−0.29,0.68) 0.432 1648
T 0.88 (0.35,1.40) 0.001 1648
K 0.26 (−0.27,0.80) 0.332 1648
Other European 0.35 (−0.25,0.96) 0.252 1648
Leg length (cm) (FOM2: 2011–2013) U 0.37 (−0.24,0.98) 0.239 1648 0.166
J −0.57 (−1.21,0.08) 0.084 1648
T 0.49 (−0.21,1.18) 0.173 1648
K 0.16 (−0.55,0.87) 0.660 1648
Other European 0.11 (−0.69,0.91) 0.788 1648
Total body bone mineral density (FOM1: 2009–2011) U 0.01 (−0.003,0.02) 0.156 2509 0.083
J −0.003 (−0.01,0.01) 0.549 2509
T 0.01 (0.003,0.03) 0.012 2509
K −0.003 (−0.01,0.01) 0.601 2509
Other European 0.002 (−0.01,0.02) 0.744 2509
Total body bone mineral density (FOM2: 2011–2013) U 0.01 (−0.003,0.02) 0.146 1614 0.421
J −0.002 (−0.02,0.01) 0.820 1614
T 0.01 (−0.01,0.02) 0.378 1614
K −0.01 (−0.02,0.01) 0.274 1614
Other European 0.001 (−0.02,0.02) 0.945 1614
Daily fat intake (g) (~32 weeks gestation) U −0.36 (−1.13,0.41) 0.358 4386 0.230
J 0.02 (−0.82,0.85) 0.971 4386
T 0.18 (−0.66,1.01) 0.678 4386
K −0.08 (−0.98,0.81) 0.856 4386
Other European −1.29 (−2.35,−0.23) 0.018 4386
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Table 2. Cont.
B—Variable Clade OR 95% CI p-Value N Model p-Value
parity (~18 weeks gestation) U 1.01 (0.85,1.20) 0.907 4617 0.741
J 1.07 (0.90,1.28) 0.447 4617
T 0.95 (0.79,1.15) 0.612 4617
K 1.01 (0.84,1.23) 0.885 4617
Other European 0.87 (0.68,1.09) 0.223 4617
Number of pregnancies after study child (child ~21 months old) U 0.95 (0.76,1.19) 0.639 4007 0.524
J 0.82 (0.64,1.05) 0.119 4007
T 0.96 (0.75,1.22) 0.722 4007
K 0.80 (0.61,1.06) 0.123 4007
Other European 0.94 (0.69,1.27) 0.687 4007
Alcohol consumption before this pregnancy U 1.15 (0.97,1.36) 0.098 4645 0.082
J 1.02 (0.85,1.22) 0.812 4645
T 0.94 (0.78,1.13) 0.495 4645
K 0.81 (0.66,0.98) 0.031 4645
Other European 0.95 (0.76,1.21) 0.695 4645
Alcohol consumption (child ~8 months old) U 0.94 (0.79,1.12) 0.500 4319 0.226
J 0.88 (0.73,1.06) 0.169 4319
T 0.89 (0.73,1.07) 0.216 4319
K 0.79 (0.65,0.98) 0.032 4319
Other European 0.84 (0.66,1.07) 0.176 4319
Quantity of alcohol mother drinks (child ~21 months old) U 1.04 (0.87,1.23) 0.679 3995 0.170
J 0.84 (0.70,1.03) 0.089 3995
T 0.95 (0.78,1.15) 0.584 3995
K 0.79 (0.64,0.98) 0.030 3995
Other European 0.96 (0.76,1.22) 0.767 3995
Quantity of alcohol mother drinks (child ~33 months old) U 0.98 (0.82,1.16) 0.796 3879 0.050
J 0.86 (0.70,1.04) 0.124 3879
T 0.85 (0.70,1.03) 0.107 3879
K 0.73 (0.59,0.91) 0.006 3879
Other European 0.84 (0.65,1.07) 0.154 3879
Quantity of alcohol mother drinks (child ~5 years old) U 1.13 (0.93,1.38) 0.206 3445 0.058
J 0.96 (0.79,1.17) 0.688 3445
T 0.91 (0.75,1.13) 0.399 3445
K 0.73 (0.59,0.92) 0.008 3445
Other European 1.00 (0.77,1.28) 0.972 3445
Years taking contraceptive pill (child ~8 years old) U 0.87 (0.69,1.09) 0.225 3056 0.170
J 0.83 (0.64,1.05) 0.121 3056
T 1.12 (0.86,1.45) 0.425 3056
K 0.82 (0.63,1.07) 0.154 3056
Other European 1.16 (0.83,1.62) 0.389 3056
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Table 2. Cont.
B—Variable Clade OR 95% CI p-Value N Model p-Value
Years taking contraceptive pill (child ~11 years old) U 0.88 (0.70,1.09) 0.243 3352 0.289
J 0.95 (0.74,1.21) 0.659 3352
T 1.00 (0.78,1.27) 0.974 3352
K 0.79 (0.61,1.03) 0.087 3352
Other European 1.22 (0.88,1.68) 0.233 3352
Frequency of alcohol consumption (May–September 2010) U 1.22 (0.93,1.60) 0.153 2036 0.425
J 1.11 (0.84,1.48) 0.467 2036
T 0.90 (0.68,1.20) 0.483 2036
K 0.92 (0.68,1.25) 0.610 2036
Other European 1.22 (0.84,1.75) 0.292 2036
Duration of breastfeeding last baby (~18 weeks gestation) U 0.97 (0.78,1.22) 0.805 2508 0.229
J 1.00 (0.79,1.28) 0.973 2508
T 1.22 (0.94,1.57) 0.127 2508
K 0.95 (0.73,1.23) 0.715 2508
Other European 1.39 (1.01,1.92) 0.044 2508
Average time spent exercising in past year (from ~18 weeks gestation to 2010) U 1.00 (0.85,1.19) 0.954 4545 0.392
J 0.97 (0.80,1.16) 0.712 4545
T 1.00 (0.83,1.21) 0.996 4545
K 0.80 (0.66,0.98) 0.028 4545
Other European 0.94 (0.75,1.19) 0.633 4545
Number of hours of activity per week (from ~18 weeks gestation to 2010) U 0.93 (0.79,1.09) 0.378 4596 0.792
J 0.93 (0.78,1.12) 0.452 4596
T 0.93 (0.78,1.13) 0.485 4596
K 0.96 (0.79,1.16) 0.648 4596
Other European 1.09 (0.86,1.38) 0.464 4596
Number of hours of vigorous activity per week (from ~18 weeks gestation to 2010) U 1.14 (0.95,1.36) 0.144 4670 0.684
J 1.02 (0.84,1.25) 0.853 4670
T 1.08 (0.90,1.32) 0.396 4670
K 0.97 (0.78,1.20) 0.753 4670
Other European 0.98 (0.76,1.26) 0.860 4670
Mother has reached menopause (child ~20 years old) U 0.98 (0.69,1.39) 0.896 2074 0.442
J 0.95 (0.65,1.38) 0.777 2074
T 0.73 (0.50,1.08) 0.112 2074
K 1.26 (0.85,1.88) 0.246 2074
Other European 1.07 (0.68,1.69) 0.761 2074
Mother’s natural mother had breast cancer (~12 weeks gestation) U 0.66 (0.38,1.14) 0.134 4509 0.679
J 0.85 (0.50,1.44) 0.542 4509
T 0.83 (0.48,1.43) 0.494 4509
K 1.09 (0.65,1.83) 0.748 4509
Other European 1.04 (0.54,1.97) 0.915 4509
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Table 2. Cont.
B—Variable Clade OR 95% CI p-Value N Model p-Value
Mother’s natural mother had breast cancer (child ~8 years old) U 0.83 (0.52,1.33) 0.439 3122 0.496
J 1.07 (0.67,1.71) 0.763 3122
T 0.61 (0.34,1.09) 0.094 3122
K 0.95 (0.56,1.60) 0.846 3122
Other European 0.68 (0.34,1.37) 0.282 3122
Mother ever had a mammogram (FOM1: 2009–2011) U 1.01 (0.66,1.55) 0.955 2577 0.408
J 0.80 (0.50,1.28) 0.348 2577
T 0.73 (0.44,1.20) 0.218 2577
K 1.18 (0.72,1.91) 0.516 2577
Other European 0.63 (0.34,1.16) 0.137 2577
Breastfed last baby (~18 weeks gestation) U 1.04 (0.77,1.39) 0.814 2509 0.537
J 1.11 (0.81,1.53) 0.519 2509
T 1.3 (0.93,1.83) 0.131 2509
K 1.05 (0.75,1.48) 0.767 2509
Other European 1.39 (0.90,2.14) 0.140 2509
Mother ever had diabetes (from ~12 weeks gestation to 2010) U 0.98 (0.58,1.67) 0.948 4772 0.428
J 1.12 (0.65,1.93) 0.686 4772
T 1.67 (1.03,2.72) 0.039 4772
K 1.28 (0.73,2.23) 0.391 4772
Other European 1.03 (0.51,2.09) 0.934 4772
Mother ever had any cancer (since child was ~6 years old to 2010) U 0.60 (0.34,1.05) 0.071 4251 0.243
J 0.67 (0.38,1.19) 0.171 4251
T 0.83 (0.49,1.41) 0.486 4251
K 1.04 (0.61,1.77) 0.882 4251
Other European 1.30 (0.74,2.29) 0.362 4251
Mother ever had an hysterectomy and/or oophorectomy (since child was ~8 years old to 2010) U 0.93 (0.60,1.43) 0.736 3728 0.955
J 0.94 (0.60,1.49) 0.808 3728
T 1.15 (0.74,1.79) 0.526 3728
K 0.86 (0.51,1.45) 0.569 3728
Other European 0.96 (0.54,1.70) 0.884 3728
Mother had ever done nightshift work (from ~18 weeks gestation to when child was ~10 years old) U 1.05 (0.88,1.25) 0.590 4771 0.947
J 0.96 (0.79,1.15) 0.636 4771
T 0.95 (0.79,1.16) 0.634 4771
K 0.95 (0.78,1.17) 0.648 4771
Other European 1.03 (0.81,1.31) 0.821 4771
Mother ever took oral contraceptives (from ~12 weeks gestation to 2013) U 1.17 (0.74,1.85) 0.491 4838 0.582
J 1.07 (0.67,1.72) 0.776 4838
T 0.86 (0.55,1.33) 0.497 4838
K 0.77 (0.49,1.21) 0.252 4838
Other European 0.75 (0.45,1.27) 0.285 4838
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Table 2. Cont.
B—Variable Clade OR 95% CI p-Value N Model p-Value
Mother ever used non-oral hormonal contraceptives (since child was ~21 months old to 2013) U 1.04 (0.85,1.28) 0.687 4474 0.817
J 0.93 (0.74,1.16) 0.528 4474
T 1.14 (0.92,1.42) 0.239 4474
K 1.02 (0.80,1.29) 0.901 4474
Other European 1.02 (0.77,1.35) 0.899 4474
Mother ever had hormone replacement therapy (since child was ~9 years old to 2010) U 1.06 (0.76,1.49) 0.724 3063 0.706
J 0.99 (0.69,1.43) 0.971 3063
T 0.90 (0.61,1.33) 0.587 3063
K 1.32 (0.91,1.91) 0.138 3063
Other European 1.05 (0.67,1.67) 0.822 3063
Mother ever taken aspirin (from ~18 weeks gestation to 2010) U 1.02 (0.86,1.22) 0.807 4848 0.355
J 1.08 (0.89,1.30) 0.445 4848
T 0.95 (0.78,1.15) 0.603 4848
K 0.81 (0.66,1.00) 0.051 4848
Other European 1.03 (0.81,1.30) 0.840 4848
Mother ever smoked (from ~18 weeks gestation to 2010) U 0.99 (0.83,1.17) 0.877 4863 0.739
J 1.02 (0.85,1.23) 0.798 4863
T 0.93 (0.77,1.13) 0.458 4863
K 0.87 (0.71,1.07) 0.178 4863
Other European 0.92 (0.72,1.16) 0.478 4863
Mother ever had an X-ray (from ~12 weeks gestation to when child was ~33 months old) U 1.02 (0.84,1.24) 0.822 4631 0.640
J 0.90 (0.73,1.11) 0.327 4631
T 0.97 (0.78,1.20) 0.773 4631
K 1.15 (0.93,1.44) 0.201 4631
Other European 0.96 (0.74,1.26) 0.777 4631
Mother exercised at least once a week (from ~18 weeks gestation to 2010) U 1.27 (0.95,1.69) 0.105 4723 0.071
J 1.24 (0.91,1.69) 0.167 4723
T 1.01 (0.76,1.36) 0.924 4723
K 0.77 (0.58,1.02) 0.066 4723
Other European 1.19 (0.81,1.76) 0.374 4723
1 Adjusted for gestational age and 10 principal components. FOM: Focus on Mothers clinic; SHBG: Sex hormone binding globulin; IGF:Insulin-like growth factor; IGFBP: Insulin-like
growth factor binding protein; BMI: Body mass index; ALSPAC: Avon Longitudinal Study of Parents and Children.
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Table 3. Major European mtDNA haplogroups and breast cancer risk factors in ALSPAC children. Regression models adjusted for age, sex and the top 10 genomic
principal components. (A) Continuous variables; (B) categorical variables. Reference is haplogroup HV.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
SHBG (nmol/L) (~8 years old) U −3.13 (−10.91,4.65) 0.429 635 0.435
J 1.05 (−6.84,8.94) 0.794 635
T −8.19 (−16.27,−0.11) 0.047 635
K −0.32 (−8.93,8.28) 0.941 635
Other European −2.52 (−12.58,7.53) 0.623 635
SHBG, nmol/L) (~15 years old) 1 U −0.71 (−5.93,4.52) 0.790 1281 0.812
J −3.64 (−9.15,1.87) 0.195 1281
T −1.67 (−7.14,3.8) 0.550 1281
K 0.85 (−5.29,6.98) 0.786 1281
Other European −1.95 (−8.86,4.96) 0.580 1281
Testosterone (nmol/L) (~15 years old) 1 U 0.01 (−0.06,0.08) 0.775 1339 0.478
J −0.05 (−0.13,0.02) 0.172 1339
T −0.004 (−0.08,0.07) 0.911 1339
K 0.05 (−0.04,0.14) 0.242 1339
Other European −0.04 (−0.14,0.06) 0.463 1339
Androstenedione (ng/dL) (~8 years old) U 0.97 (−6.49,8.42) 0.799 583 0.948
J −0.64 (−8.18,6.9) 0.867 583
T 2.75 (−5.10,10.61) 0.492 583
K −1.13 (−9.24,6.97) 0.783 583
Other European −2.80 (−12.70,7.09) 0.578 583
DHEAS(ug/dL) (~8 years old) 2 U −0.02 (−7.00,6.95) 0.995 585 0.269
J −1.83 (−8.91,5.26) 0.613 585
T 6.29 (−1.04,13.63) 0.093 585
K −3.89 (−11.51,3.73) 0.317 585
Other European −5.05 (−14.35,4.25) 0.286 585
IGF-I (ng/mL) (cord blood) 3 U 6.38 (−4.09,16.85) 0.232 442 0.125
J 11.50 (−0.87,23.87) 0.068 442
T −3.09 (−14.72,8.54) 0.602 442
K 6.36 (−6.65,19.37) 0.337 442
Other European 14.71 (0.55,28.87) 0.042 442
IGF-I (~7 years old) U −6.19 (−22.93,10.55) 0.468 340 0.347
J 8.42 (−8.53,25.37) 0.329 340
T −13.79 (−31.15,3.57) 0.119 340
K 3.32 (−16.52,23.16) 0.742 340
Other European −10.36 (−32.65,11.92) 0.361 340
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Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
IGF-I (ng/mL) (~8 years old) U 6.41 (−13.53,26.34) 0.528 317 0.499
J −19.44 (−42.05,3.18) 0.092 317
T −2.37 (−22.9,18.16) 0.821 317
K −5.54 (−27.13,16.05) 0.614 317
Other European 2.74 (−25.34,30.81) 0.848 317
IGF-II (ng/mL) (cord blood) 3 U −9.90 (−32.12,12.32) 0.382 443 0.032
J −24.76 (−51.01,1.49) 0.064 443
T 23.21 (−1.46,47.89) 0.065 443
K −24.67 (−52.29,2.95) 0.080 443
Other European −3.16 (−33.22,26.89) 0.836 443
IGF-II (ng/mL) (~7 years old) U −33.08 (−95.43,29.26) 0.296 149 0.647
J −13.87 (−69.00,41.26) 0.620 149
T −53.36 (−120,12.9519) 0.114 149
K −8.39 (−77.90,61.13) 0.812 149
Other European 4.21 (−74.08,82.51) 0.915 149
IGFBP-3 (ng/mL) (cord blood) 3 U −60.05 (−346.54,226.44) 0.679 137 0.856
J −65.89 (−413.24,281.45) 0.708 137
T 132.24 (−118.57,383.05) 0.299 137
K −37.07 (−352.6,278.46) 0.816 137
Other European −26.71 (−376.79,323.37) 0.880 137
IGFBP-3 (ng/mL) (~7 years old) U −77.05 (−440,29.44) 0.679 340 0.439
J 76.89 (−290.00,447.99) 0.684 340
T −320.00 (−700,63.7442) 0.103 340
K −180.00 (−620.00,251.58) 0.408 340
Other European −320.00 (−810.00,169.81) 0.201 340
IGFBP-3 (ng/mL) (~8 years old) U 22.75 (−572.91,618.40) 0.940 317 0.674
J 77.72 (−598.04,753.47) 0.821 317
T 150.74 (−462.65,764.13) 0.629 317
K 404.59 (−240.45,1049.63) 0.218 317
Other European −412.02 (−1253.45,429.42) 0.336 317
Age at menarche (months) 1 U 1.30 (0.29,2.89) 0.108 2728 0.254
J −0.85 (−2.56,0.86) 0.332 2728
T 0.08 (−1.64,1.79) 0.931 2728
K −1.30 (−3.30,0.69) 0.201 2728
Other European −0.56 (−2.75,1.63) 0.616 2728
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Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
BMI (kg/m2) (~12 months old) U 0.15 (−0.14,0.44) 0.313 773 0.014
J −0.13 (−0.48,0.22) 0.478 773
T 0.25 (−0.05,0.54) 0.099 773
K −0.34 (−0.67,0.00) 0.047 773
Other European 0.40 (0.02,0.79) 0.041 773
BMI (kg/m2) (~25 months old) U 0.13 (−0.19,0.44) 0.435 675 0.507
J −0.16 (−0.54,0.23) 0.427 675
T 0.21 (−0.12,0.53) 0.213 675
K −0.06 (−0.44,0.31) 0.746 675
Other European 0.22 (−0.21,0.65) 0.310 675
BMI (kg/m2) (~37 months old) U 0.12 (−0.18,0.43) 0.429 691 0.143
J −0.21 (−0.58,0.15) 0.254 691
T 0.13 (−0.18,0.45) 0.410 691
K 0.12 (−0.24,0.48) 0.518 691
Other European 0.48 (0.06,0.89) 0.024 691
BMI (kg/m2) (~61 months old) U 0.13 (−0.23,0.48) 0.488 664 0.103
J −0.08 (−0.50,0.35) 0.725 664
T 0.28 (−0.07,0.64) 0.118 664
K −0.05 (−0.45,0.36) 0.827 664
Other European 0.61 (0.14,1.08) 0.012 664
BMI (kg/m2) (~7 years old) U −0.04 (−0.21,0.13) 0.647 5345 0.898
J −0.03 (−0.21,0.15) 0.721 5345
T 0.01 (−0.18,0.19) 0.945 5345
K 0.09 (−0.11,0.29) 0.378 5345
Other European 0.06 (−0.17,0.28) 0.611 5345
BMI (kg/m2) (~9 years old) U 0.01 (−0.23,0.25) 0.943 5106 0.981
J 0.03 (−0.22,0.28) 0.822 5106
T −0.10 (−0.36,0.16) 0.456 5106
K −0.01 (−0.29,0.28) 0.970 5106
Other European 0.01 (−0.31,0.32) 0.968 5106
BMI (kg/m2) (~11 years old) U −0.09 (−0.38,0.20) 0.551 4764 0.768
J 0.01 (−0.30,0.33) 0.927 4764
T 0.01 (−0.31,0.33) 0.940 4764
K −0.03 (−0.38,0.32) 0.864 4764
Other European 0.27 (−0.12,0.66) 0.179 4764
Genes 2018, 9, 395 17 of 31
Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
BMI (kg/m2) (~13 years old) U 0.004 (−0.30,0.31) 0.981 4516 0.787
J −0.05 (−0.39,0.28) 0.755 4516
T −0.02 (−0.36,0.32) 0.905 4516
K −0.24 (−0.61,0.13) 0.209 4516
Other European 0.15 (−0.27,0.56) 0.483 4516
BMI (kg/m2) (~15 years old) U −0.08 (−0.43,0.27) 0.656 3694 0.219
J 0.13 (−0.24,0.49) 0.499 3694
T −0.18 (−0.56,0.20) 0.354 3694
K −0.04 (−0.44,0.36) 0.842 3694
Other European 0.49 (0.04,0.95) 0.033 3694
BMI (kg/m2) (~17 years old) U −0.15 (−0.56,0.27) 0.490 3327 0.812
J 0.17 (−0.27,0.62) 0.445 3327
T −0.02 (−0.47,0.43) 0.931 3327
K −0.10 (−0.58,0.39) 0.700 3327
Other European 0.24 (−0.33,0.80) 0.417 3327
BMI (kg/m2) (~11 years old, puberty questionnaire) U −0.04 (−0.40,0.31) 0.813 2874 0.583
J 0.03 (−0.34,0.39) 0.886 2874
T 0.03 (−0.35,0.41) 0.878 2874
K 0.36 (−0.07,0.79) 0.099 2874
Other European −0.17 (−0.63,0.30) 0.479 2874
BMI (kg/m2) (~13 years old, puberty questionnaire) U −0.11 (−0.49,0.26) 0.554 2889 0.604
J −0.22 (−0.62,0.19) 0.292 2889
T −0.19 (−0.60,0.22) 0.355 2889
K −0.36 (−0.81,0.10) 0.126 2889
Other European 0.05 (−0.46,0.55) 0.861 2889
BMI (kg/m2) (~15 years old, puberty questionnaire) U −0.06 (−0.44,0.33) 0.768 2505 0.456
J 0.25 (−0.16,0.66) 0.237 2505
T −0.05 (−0.47,0.37) 0.825 2505
K −0.15 (−0.62,0.32) 0.539 2505
Other European 0.40 (−0.12,0.92) 0.135 2505
BMI (kg/m2) (~17 years old, puberty questionnaire) U −0.24 (−0.66,0.19) 0.281 2374 0.123
J 0.38 (−0.06,0.83) 0.093 2374
T 0.21 (−0.25,0.67) 0.373 2374
K −0.03 (−0.54,0.48) 0.904 2374
Other European 0.52 (−0.05,1.09) 0.072 2374
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Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
Birth weight (g) U −7.46 (−39.89,24.96) 0.652 6838 0.584
J −5.43 (−40.22,29.36) 0.759 6838
T −25.25 (−61.23,10.74) 0.169 6838
K −12.34 (−50.81,26.12) 0.529 6838
Other European −33.86 (−77.51,9.79) 0.128 6838
Weight (kg) (~12 months old) U 0.10 (−0.13,0.34) 0.396 775 0.092
J −0.05 (−0.34,0.23) 0.718 775
T 0.22 (−0.03,0.46) 0.079 775
K −0.24 (−0.51,0.03) 0.081 775
Other European 0.16 (−0.15,0.48) 0.309 775
Weight (kg) (~25 months old) U 0.15 (−0.17,0.48) 0.358 718 0.301
J 0.0002 (−0.39,0.39) 0.999 718
T 0.31 (−0.01,0.64) 0.061 718
K −0.19 (−0.57,0.19) 0.317 718
Other European 0.02 (−0.42,0.45) 0.938 718
Weight (kg) (~37 months old) U 0.20 (−0.20,0.60) 0.330 699 0.745
J −0.09 (−0.58,0.39) 0.704 699
T 0.22 (−0.20,0.64) 0.301 699
K −0.01 (−0.48,0.46) 0.966 699
Other European 0.24 (−0.31,0.78) 0.395 699
Weight (kg) (~61 months old) U 0.40 (−0.25,1.05) 0.229 667 0.494
J 0.18 (−0.59,0.95) 0.648 667
T 0.53 (−0.13,1.18) 0.113 667
K −0.18 (−0.93,0.56) 0.626 667
Other European 0.31 (−0.56,1.18) 0.484 667
Weight (kg) (~7 years old) U −0.11 (−0.48,0.26) 0.573 5346 0.974
J 0.03 (−0.37,0.42) 0.896 5346
T −0.02 (−0.42,0.39) 0.937 5346
K 0.13 (−0.32,0.57) 0.573 5346
Other European −0.05 (−0.54,0.45) 0.846 5346
Weight (kg) (~9 years old) U 0.01 (−0.60,0.62) 0.981 5149 0.877
J 0.28 (−0.37,0.92) 0.402 5149
T 0.03 (−0.63,0.69) 0.937 5149
K 0.04 (−0.68,0.76) 0.909 5149
Other European −0.37 (−1.18,0.44) 0.368 5149
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Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
Weight (kg, DEXA) (~9 years old) U 0.04 (−0.57,0.65) 0.892 4910 0.802
J 0.36 (−0.28,1.01) 0.273 4910
T 0.03 (−0.63,0.69) 0.931 4910
K −0.03 (−0.76,0.69) 0.931 4910
Other European −0.36 (−1.18,0.45) 0.386 4910
Weight (kg) (~11 years old) U −0.17 (−1.02,0.67) 0.690 4770 0.972
J 0.21 (−0.70,1.13) 0.646 4770
T 0.15 (−0.78,1.09) 0.748 4770
K 0.14 (−0.88,1.16) 0.787 4770
Other European 0.31 (−0.83,1.45) 0.595 4770
Weight (kg) (~13 years old) U 0.18 (−0.77,1.13) 0.715 4516 0.931
J 0.30 (−0.73,1.33) 0.568 4516
T 0.42 (−0.62,1.46) 0.430 4516
K −0.28 (−1.43,0.87) 0.631 4516
Other European 0.08 (−1.20,1.36) 0.905 4516
Weight (kg) (~15 years old) U −0.07 (−1.20,1.07) 0.910 3694 0.242
J 0.91 (−0.29,2.12) 0.136 3694
T −0.41 (−1.66,0.83) 0.513 3694
K 0.04 (−1.29,1.36) 0.957 3694
Other European 1.45 (−0.05,2.94) 0.057 3694
Weight (kg) (~17 years old) U −0.21 (−1.52,1.11) 0.756 3329 0.902
J 0.59 (−0.82,2.00) 0.411 3329
T 0.05 (−1.38,1.48) 0.945 3329
K −0.05 (−1.58,1.49) 0.953 3329
Other European 0.77 (−1.03,2.56) 0.402 3329
Weight (kg) (~11 years old, puberty questionnaire) U 0.18 (−0.71,1.07) 0.693 3153 0.757
J 0.44 (−0.49,1.36) 0.356 3153
T 0.18 (−0.77,1.13) 0.714 3153
K 0.57 (−0.51,1.65) 0.300 3153
Other European −0.42 (−1.61,0.76) 0.484 3153
Weight (kg) (~13 years old, puberty questionnaire) U 0.51 (−0.62,1.64) 0.373 3053 0.959
J 0.08 (−1.11,1.28) 0.891 3053
T 0.30 (−0.92,1.52) 0.629 3053
K 0.00 (−1.37,1.36) 0.998 3053
Other European 0.36 (−1.17,1.89) 0.644 3053
Genes 2018, 9, 395 20 of 31
Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
Weight (kg) (~15 years old, puberty questionnaire) U −0.29 (−1.52,0.95) 0.649 2659 0.567
J 0.77 (−0.55,2.09) 0.255 2659
T 0.19 (−1.17,1.55) 0.787 2659
K 0.41 (−1.10,1.92) 0.596 2659
Other European 1.25 (−0.43,2.93) 0.145 2659
Weight (kg) (~17 years old, puberty questionnaire) U −0.27 (−1.64,1.10) 0.699 2476 0.092
J 1.82 (0.39,3.24) 0.012 2476
T 0.45 (−1.03,1.93) 0.549 2476
K 0.20 (−1.45,1.85) 0.811 2476
Other European 1.60 (−0.20,3.40) 0.081 2476
Height (cm) (~25 months old) U −0.05 (−0.75,0.64) 0.881 675 0.130
J 0.22 (−0.62,1.07) 0.604 675
T 0.32 (−0.39,1.03) 0.384 675
K −0.64 (−1.47,0.18) 0.125 675
Other European −0.99 (−1.93,−0.05) 0.040 675
Height (cm) (~37 months old) U 0.23 (−0.57,1.03) 0.579 691 0.547
J 0.28 (−0.67,1.24) 0.561 691
T 0.15 (−0.68,0.98) 0.724 691
K −0.51 (−1.45,0.43) 0.286 691
Other European −0.67 (−1.76,0.41) 0.222 691
Height (cm) (~61 months old) U 0.67 (−0.37,1.71) 0.206 665 0.134
J 0.79 (−0.44,2.02) 0.207 665
T 0.44 (−0.6,1.48) 0.407 665
K −0.46 (−1.64,0.73) 0.447 665
Other European −1.18 (−2.56,0.2) 0.093 665
Sitting height (kg) (~61 months old) U 0.33 (−0.25,0.9) 0.262 667 0.722
J 0.21 (−0.47,0.89) 0.545 667
T 0.15 (−0.43,0.72) 0.617 667
K −0.13 (−0.79,0.52) 0.694 667
Other European −0.28 (−1.04,0.48) 0.472 667
Height (cm) (~7 years old) U −0.07 (−0.50,0.36) 0.752 5350 0.885
J 0.22 (−0.25,0.68) 0.365 5350
T −0.03 (−0.51,0.44) 0.890 5350
K −0.03 (−0.55,0.49) 0.915 5350
Other European −0.21 (−0.79,0.37) 0.484 5350
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A—Variable Clade Beta 95% CI p-Value N Model p-Value
Sitting height (cm) (~7 years old) U −0.02 (−0.24,0.21) 0.878 5351 0.949
J 0.03 (−0.21,0.27) 0.821 5351
T 0.01 (−0.24,0.25) 0.966 5351
K −0.02 (−0.29,0.25) 0.884 5351
Other European −0.15 (−0.45,0.15) 0.324 5351
Height (cm) (~9 years old) U 0.07 (−0.44,0.59) 0.778 5108 0.213
J 0.49 (−0.06,1.04) 0.081 5108
T 0.33 (−0.23,0.89) 0.247 5108
K 0.19 (−0.43,0.80) 0.551 5108
Other European −0.49 (−1.18,0.20) 0.165 5108
Sitting height (cm) (~9 years old) U 0.11 (−0.15,0.37) 0.397 5145 0.178
J 0.28 (0.01,0.55) 0.042 5145
T 0.17 (−0.10,0.45) 0.221 5145
K 0.06 (−0.24,0.37) 0.680 5145
Other European −0.20 (−0.54,0.14) 0.252 5145
Height (cm) (~11 years old) U −0.02 (−0.63,0.59) 0.946 4765 0.614
J 0.32 (−0.34,0.98) 0.342 4765
T 0.22 (−0.45,0.90) 0.517 4765
K 0.36 (−0.38,1.10) 0.342 4765
Other European −0.43 (−1.26,0.39) 0.304 4765
Sitting height (cm) (~11 years old) U −0.08 (−0.40,0.23) 0.604 4769 0.784
J 0.10 (−0.24,0.44) 0.566 4769
T 0.10 (−0.25,0.45) 0.558 4769
K 0.11 (−0.28,0.49) 0.587 4769
Other European −0.20 (−0.63,0.23) 0.362 4769
Height (cm) (~13 years old) U 0.18 (−0.49,0.84) 0.601 4559 0.162
J 0.67 (−0.05,1.39) 0.069 4559
T 0.67 (−0.06,1.39) 0.072 4559
K 0.46 (−0.34,1.26) 0.262 4559
Other European −0.39 (−1.28,0.51) 0.394 4559
Sitting height (cm) (~13 years old) U 0.07 (−0.29,0.43) 0.694 4531 0.106
J 0.34 (−0.05,0.73) 0.087 4531
T 0.35 (−0.04,0.74) 0.080 4531
K 0.29 (−0.15,0.72) 0.195 4531
Other European −0.31 (−0.79,0.17) 0.206 4531
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Height (cm) (~15 years old) U 0.21 (−0.47,0.89) 0.551 3702 0.514
J 0.75 (0.02,1.47) 0.043 3702
T 0.16 (−0.58,0.90) 0.667 3702
K 0.22 (−0.57,1.01) 0.589 3702
Other European 0.03 (−0.86,0.93) 0.940 3702
Sitting height (cm) (~15 years old) U −0.07 (−0.47,0.33) 0.739 3139 0.188
J 0.52 (0.09,0.94) 0.017 3139
T 0.11 (−0.33,0.54) 0.630 3139
K 0.15 (−0.32,0.62) 0.537 3139
Other European −0.17 (−0.71,0.37) 0.534 3139
Height (cm) (~17 years old) U 0.23 (−0.44,0.91) 0.496 3330 0.975
J 0.14 (−0.58,0.86) 0.701 3330
T 0.15 (−0.59,0.88) 0.693 3330
K 0.27 (−0.52,1.05) 0.507 3330
Other European 0.06 (−0.86,0.98) 0.904 3330
Height (cm) (~11 years old, puberty questionnaire) U 0.32 (−0.45,1.10) 0.415 3167 0.656
J 0.45 (−0.35,1.26) 0.271 3167
T 0.56 (−0.28,1.39) 0.191 3167
K 0.20 (−0.74,1.14) 0.677 3167
Other European −0.21 (−1.23,0.80) 0.680 3167
Height (cm) (~13 years old, puberty questionnaire) U 1.09 (0.19,1.98) 0.017 3277 0.020
J 1.19 (0.23,2.14) 0.015 3277
T 1.22 (0.26,2.19) 0.013 3277
K 0.71 (−0.37,1.79) 0.200 3277
Other European 0.14 (−1.06,1.33) 0.821 3277
Height (cm) (~15 years old, puberty questionnaire) U 0.27 (−0.63,1.16) 0.559 2797 0.502
J 0.34 (−0.62,1.30) 0.482 2797
T 0.33 (−0.66,1.31) 0.517 2797
K 1.10 (−0.02,2.23) 0.054 2797
Other European −0.15 (−1.37,1.07) 0.809 2797
Height (cm) (~17 years old, puberty questionnaire) U 0.11 (−0.74,0.95) 0.802 2567 0.846
J 0.61 (−0.28,1.51) 0.179 2567
T −0.03 (−0.94,0.88) 0.944 2567
K 0.18 (−0.84,1.19) 0.729 2567
Other European −0.06 (−1.19,1.07) 0.918 2567
Genes 2018, 9, 395 23 of 31
Table 3. Cont.
A—Variable Clade Beta 95% CI p-Value N Model p-Value
BMD (g/cm2) (~9 years old) U −0.002 (−0.006,0.003) 0.482 4910 0.691
J −0.0005 (−0.005,0.004) 0.845 4910
T 0.003 (−0.002,0.008) 0.182 4910
K 0.001 (−0.004,0.006) 0.622 4910
Other European 0.0002 (−0.006,0.006) 0.939 4910
BMD (g/cm2) (~11 years old) U −0.002 (−0.007,0.003) 0.461 4699 0.498
J 0.001 (−0.005,0.007) 0.740 4699
T 0.004 (−0.002,0.010) 0.159 4699
K 0.004 (−0.003,0.010) 0.252 4699
Other European 0.002 (−0.006,0.009) 0.656 4699
BMD (g/cm2 (~13 years old) U −0.003 (−0.010,0.005) 0.489 3903 0.635
J 0.004 (−0.004,0.012) 0.333 3903
T 0.004 (−0.004,0.013) 0.298 3903
K 0.004 (−0.005,0.013) 0.389 3903
Other European 0.001 (−0.009,0.011) 0.807 3903
BMD (g/cm2) (~15 years old) U −0.006 (−0.015,0.002) 0.147 3550 0.206
J 0.004 (−0.005,0.012) 0.432 3550
T 0.004 (−0.005,0.013) 0.362 3550
K 0.005 (−0.005,0.015) 0.311 3550
Other European 0.008 (−0.004,0.019) 0.183 3550
BMD (g/cm2) (~17 years old) U −0.001 (−0.001,0.008) 0.884 3219 0.866
J 0.001 (−0.009,0.010) 0.840 3219
T 0.006 (−0.004,0.016) 0.251 3219
K 0.001 (−0.010,0.011) 0.863 3219
Other European 0.005 (−0.008,0.017) 0.459 3219
B—Variable Clade OR 95% CI p-Value N model p-Value
YYP was breastfed as a baby U 1.08 (0.94,1.26) 0.276 6357 0.630
J 1.13 (0.96,1.31) 0.139 6357
T 1.02 (0.87,1.20) 0.783 6357
K 1.01 (0.85,1.20) 0.895 6357
Other European 0.96 (0.79,1.17) 0.672 6357
Frequency YP has a drink containing alcohol (~17 years old, questionnaire) U 0.99 (0.81,1.21) 0.897 3126 0.893
J 1.08 (0.88,1.35) 0.432 3126
T 1.04 (0.83,1.30) 0.754 3126
K 1.08 (0.85,1.38) 0.524 3126
Other European 1.14 (0.87,1.48) 0.359 3126
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B—Variable Clade OR 95% CI p-Value N model p-Value
Frequency YP has a drink containing alcohol (~17 years old, clinic visit) U 1.12 (0.90,1.39) 0.314 2655 0.629
J 1.21 (0.96,1.52) 0.107 2655
T 1.04 (0.82,1.32) 0.761 2655
K 1.00 (0.78,1.28) 0.996 2655
Other European 1.13 (0.83,1.52) 0.454 2655
Frequency respondent has a drink containing alcohol (~19 years old) U 0.94 (0.74,1.20) 0.615 2136 0.862
J 1.07 (0.84,1.39) 0.572 2136
T 0.96 (0.73,1.26) 0.770 2136
K 1.15 (0.86,1.55) 0.337 2136
Other European 1.04 (0.76,1.45) 0.806 2136
Over the past year frequency YP had a drink containing alcohol (~21 years old) U 1.06 (0.86,1.30) 0.578 2701 0.568
J 1.11 (0.89,1.38) 0.385 2701
T 1.11 (0.87,1.40) 0.430 2701
K 0.91 (0.70,1.17) 0.477 2701
Other European 1.23 (0.91,1.67) 0.166 2701
Over the past year frequency YP had a drink containing alcohol (~23 years old) U 0.87 (0.70,1.08) 0.202 2499 0.710
J 1.03 (0.82,1.30) 0.804 2499
T 0.98 (0.77,1.25) 0.853 2499
K 0.86 (0.66,1.12) 0.257 2499
other European 0.99 (0.72,1.35) 0.935 2499
Frequency of physical activity during the past month (8–12 years old) U 0.94 (0.80,1.12) 0.507 5556 0.679
J 0.97 (0.81,1.16) 0.752 5556
T 1.06 (0.89,1.28) 0.500 5556
K 1.12 (0.91,1.36) 0.262 5556
Other European 1.08 (0.87,1.35) 0.474 5556
Frequency of physical activity during the past month (13–18 years old) U 0.94 (0.80,1.11) 0.460 5573 0.851
J 0.92 (0.78,1.08) 0.329 5573
T 0.94 (0.79,1.12) 0.505 5573
K 1.04 (0.86,1.26) 0.669 5573
Other European 0.99 (0.80,1.22) 0.924 5573
Frequency of physical activity during the past year (13–18 years old) U 1.02 (0.86,1.21) 0.854 4540 0.906
J 1.03 (0.86,1.23) 0.772 4540
T 1.01 (0.84,1.22) 0.904 4540
K 1.14 (0.92,1.39) 0.228 4540
Other European 1.05 (0.84,1.32) 0.646 4540
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B—Variable Clade OR 95% CI p-Value N model p-Value
YP was breastfed as a baby U 0.91 (0.75,1.10) 0.324 6383 0.820
J 0.92 (0.75,1.12) 0.393 6383
T 0.93 (0.75,1.15) 0.498 6383
K 1.03 (0.81,1.30) 0.826 6383
Other European 1.05 (0.80,1.36) 0.740 6383
YP is a biological parent (21–23 years old) U 0.55 (0.31,0.98) 0.043 3563 0.205
J 0.92 (0.55,1.54) 0.760 3563
T 0.94 (0.56,1.59) 0.830 3563
K 0.60 (0.30,1.21) 0.155 3563
Other European 1.31 (0.73,2.35) 0.374 3563
YP ever took oral contraceptives (from 8 to 22 years old) U 1.05 (0.85,1.29) 0.665 3483 0.512
J 1.13 (0.91,1.41) 0.273 3483
T 1.02 (0.81,1.27) 0.886 3483
K 1.16 (0.90,1.49) 0.254 3483
Other European 0.85 (0.64,1.13) 0.252 3483
YP ever used non-oral hormonal contraceptives (from 17 to 22 years old) U 1.32 (0.95,1.82) 0.096 2709 0.529
J 1.11 (0.78,1.58) 0.572 2709
T 0.94 (0.64,1.38) 0.749 2709
K 1.09 (0.73,1.64) 0.659 2709
Other European 0.85 (0.51,1.42) 0.529 2709
Teenager has drunk alcohol (~13 years old) U 1.09 (0.88,1.35) 0.436 3117 0.817
J 1.09 (0.86,1.37) 0.484 3117
T 0.96 (0.75,1.22) 0.729 3117
K 1.01 (0.78,1.31) 0.945 3117
Other European 0.88 (0.65,1.19) 0.408 3117
YP has ever drunk alcohol (~17 years old) U 1.00 (0.64,1.57) 0.998 3316 0.962
J 1.17 (0.70,1.95) 0.549 3316
T 1.21 (0.71,2.07) 0.479 3316
K 1.05 (0.60,1.81) 0.871 3316
Other European 0.92 (0.52,1.62) 0.762 3316
YP ever smoked (from 14 to 23 years old) U 1.16 (0.98,1.38) 0.088 5615 0.262
J 1.06 (0.88,1.27) 0.564 5615
T 1.06 (0.88,1.28) 0.524 5615
K 1.14 (0.93,1.40) 0.210 5615
Other European 0.88 (0.70,1.10) 0.247 5615
Genes 2018, 9, 395 26 of 31
Table 3. Cont.
B—Variable Clade OR 95% CI p-Value N model p-Value
YP ever had diabetes (from 11 to 23 years old) U 3.50 (1.22,10.06) 0.020 3895 0.257
J 3.05 (0.96,9.70) 0.058 3895
T 1.92 (0.49,7.48) 0.345 3895
K 1.50 (0.31,7.28) 0.614 3895
Other European 2.07 (0.42,10.08) 0.369 3895
YP ever had an X-ray (from 6 months to 15 years old) U 1.04 (0.83,1.30) 0.720 6464 0.158
J 1.08 (0.86,1.37) 0.507 6464
T 1.00 (0.78,1.28) 0.995 6464
K 0.78 (0.58,1.04) 0.093 6464
Other European 1.31 (0.99,1.73) 0.056 6464
1 Only girls in the analysis. 2 Natural logarithm of DHEAS levels. 3 Adjusted for gestational age, sex and 10 principal components. DHEAS: Dehydroepiandrosterone; BMD: Total bone
mineral density; YP: Young person; DEXA: dual-energy X-ray absorptiometry.
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4. Discussion
In this study we have not found evidence that major mtDNA haplogroups underlie differences in
breast cancer risk factor distribution. This finding in some way supports previous research showing
that mtDNA lineages are not associated with breast cancer risk [23,48], although it is still possible that
mtDNA variation directly affects cancer development without going through any of the risk factors
investigated here. However, we did not observe any associations with cancer-specific traits available
in the cohort, such as any cancer diagnosis in the mother or a breast cancer diagnosis in her biological
mother. In addition, no association was evident with having had a mammogram either. Conversely,
if mtDNA variation plays a role in breast cancer onset via any of the tested exposures it might represent
a small increase in risk. Nevertheless, large scale case-control studies are needed to properly examine
the association of mtDNA haplogroups with breast cancer.
We tried to reduce sources of bias such as small sample sizes and population stratification by
using the ALSPAC cohort, where we had over 7700 individuals with mtDNA haplogroup data who
were of European genomic ancestry or self-identified as being of White ethnicity. In addition, we ran
regression models adjusted for principal components that reflect population structure in the South
West region of the UK. Because ALSPAC has collected such a comprehensive set of phenotypes we
were also able to examine most of the established and possible breast cancer risk factors.
Among the limitations of our study, the fact that a handful of traits examined had a low number
of observations, in particular the hormone measures, decreased our confidence in these results.
The minimum difference detectable with 80% power was an OR of 1.2 for the binary variables,
as estimated using mitPower. In addition, some of the derived variables grouped all instances of
a phenotype together, which may have prevented us from noticing an effect that depended on the
frequency of such a phenotype.
Pre-Bonferroni correction, we detected associations of mtDNA haplogroups with body
composition variables (mainly BMI, weight, height), which were seen in mothers as well as children
and at various instances across the lifetime. A few earlier studies have shown an association of mtDNA
haplogroups with obesity and obesity-related traits [17,49,50], while others reported no evidence of
association [51,52]. In our analysis these associations have not survived multiple testing correction,
so it is possible that they have arisen by chance or are the result of persisting population stratification
(as different subsamples of mothers and children responded to questionnaires and were involved in
the clinics), given that height and BMI are considerably structured across Europe [53]. On the other
hand, we did not find any discernible stratification beyond what was accounted for by the use of
genome-wide principal components, in agreement with a recent study that examined Y chromosome
haplogroups in ALSPAC and showed that clustering by male lineage did not affect the association
between autosomal single nucleotide polymorphisms (SNPs) and BMI [44].
Whilst we did not have a replication cohort to confirm our findings, the analysis was run in two
groups of individuals, albeit related, each with a different set of phenotypes. Further investigation
is needed to strengthen the results presented here; however, these could prove useful to generate
hypotheses for future, more powerful studies.
5. Conclusions
Well-established and possible breast cancer risk factors were not found to be associated with
mtDNA haplogroups in ALSPAC, a cohort of predominantly European ancestry. This study can
serve as the basis for a further detailed analysis of the influence of mtDNA variation on nutritional,
anthropometric and lifestyle exposures that underlie the susceptibility to breast cancer and other
cancer types.
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